efficacy results for loxo-101 in trk fusion cancers
Published 7 years ago • 1.6K plays • Length 0:54Download video MP4
Download video MP3
Similar videos
-
0:52
the impact of trk inhibitor loxo-101 (larotrectinib) on patients with trk fusion cancers
-
1:20
updated data with larotrectinib in trk fusion-positive solid tumors
-
0:47
promising data for loxo-292 in thyroid cancers
-
1:29
dr. demetri on larotrectinib in trk-fusion gi cancers
-
3:20
approaching treatment for trk fusion–positive cancers
-
2:03
dr. drilon on efficacy results with loxo-292 in ret-altered solid tumors
-
5:08
larotrectinib for ntrk fusions: patient selection
-
1:15
larotrectinib, a trk inhibitor for patients with solid tumors
-
0:49
next steps for loxo-292 in ret-mutant medullary thyroid cancer
-
1:06
updated response findings with larotrectinib in trk cancers
-
6:00
efficacy of trk inhibitors
-
1:53
investigating ros1 and trk rearrangements in lung cancer
-
1:12
highlighting promising trk inhibitors for the treatment of thyroid cancer
-
1:06
positive larotrectinib data for trk fusion cancer presented at esmo
-
4:25
updated data for larotrectinib
-
2:10
how will larotrectinib be used?
-
3:58
libretto-001: targeting ret fusions in advanced-stage nsclc
-
3:26
preliminary safety/efficacy data for larotrectinib
-
5:21
cornelis van tilburg, asco 2019 - larotrectinib in pediatric trk fusion cancer